Avexxin, a VP portfolio company, raises additional funding from existing shareholders. Amount undisclosed.
We participate in numerous events promoting our portfolio companies and meeting our clients.
Lacerta Bio, see www.lacertabio.com, merges with Ventac Partners to strengthen their position in the US market. Carlos N. Velez, Lacerta's Founder and CEO, becomes partner in Ventac Partners. A pdf copy of the joined press release announced is available here.
Ventac Partners Denmark has been appointed the status of a Gazelle Growth Company for 2014 by the Danish newspaper Borsen. Ventac Partners is one of 1,500 companies receiving the prestigious honor for 2014 of a total of ½ million companies examined. To become a Gazelle Growth Company the company has to show continuous growth over a period of four years, minimum a doubling of the top line result, and a positive result year over year.
Clinical Network Services (CNS), an integrated service consultancy focusing on preclinical and early clinical project implementation and Ventac Partners sign cooperative partnership to provide joint services to global clients. See our joint press release for further details.
Roche has agreed to acquire Santaris Pharma, a pioneer in the emerging era of RNA-targeting therapeutics via its proprietary Locked Nucleic Acid (LNA) platform. The acquisition, which is subject to customary closing conditions, is expected to close in August 2014. Roche plans to maintain Santaris Pharma’s operations in Denmark, where the existing site will be renamed Roche Innovation Center Copenhagen. Under the terms of the agreement, Roche will make an upfront cash payment of USD 250 million to Santaris Pharma shareholders and make additional contingent payments of up to USD 200 million based on the achievement of certain predetermined milestones.
Ventac Partners invited to write an article about funding of life science companies for the Australian Biotech Association’s July issue of Australasian BioTechnology on Manufacturing, money and medtech. To access the journal, please follow this link (pages 16-17).
Boulder Diagnostics Inc., a VP portfolio in vitro diagnostics company that focuses on identifying, developing, and marketing new diagnostic technologies for underserved markets was sold to Oxford Immune.
Avexxin, a VP portfolio company, announces that its clinical phase I/IIa trial encompassing 68 patients suffering from mild-to-moderate psoriasis has been completed. Study data confirm that AVX001 is safe at the doses given; moreover, 1/3 of the patients receiving the highest dose were benefiting from the treatment. As AVX001's Maximum Tolerated Dose was not reached, a further study using higher compound doses is currently being planned.
Ventac Partners organizes a course at the Asia BioInvest 2014 conference in Hong Kong (June 3). The course, entitled "Building a Successful Biotech Company – Lessons in Entrepreneurship in the Life Sciences", is designed to take life science entrepreneurs through the critical steps of the entrepreneurship process, from the early scientific discovery through venture funding, and the various growth phases of a successful biotech company. For more information, please follow this link.